Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLNN 
Clene Inc. (CLNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CLNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.43
1 Year Target Price $30.43
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.16% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.49M USD | Price to earnings Ratio - | 1Y Target Price 30.43 |
Price to earnings Ratio - | 1Y Target Price 30.43 | ||
Volume (30-day avg) 6 | Beta 0.57 | 52 Weeks Range 2.28 - 7.10 | Updated Date 09/17/2025 |
52 Weeks Range 2.28 - 7.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -21718.52% |
Management Effectiveness
Return on Assets (TTM) -52.86% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 77053343 | Price to Sales(TTM) 222 |
Enterprise Value 77053343 | Price to Sales(TTM) 222 | ||
Enterprise Value to Revenue 269.42 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 10030400 | Shares Floating 7152048 |
Shares Outstanding 10030400 | Shares Floating 7152048 | ||
Percent Insiders 30.84 | Percent Institutions 16.42 |
Upturn AI SWOT
Clene Inc.
Company Overview
History and Background
Clene Inc., founded in 2012, focuses on developing bioenergetic nanocatalysis medicines. It leverages its proprietary technology platform to create a pipeline of products that aim to treat neurodegenerative diseases.
Core Business Areas
- Neurology: Developing therapeutics for neurodegenerative diseases like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease using nanocrystalline catalysts.
Leadership and Structure
Rob Etherington serves as the President and CEO. The company operates with a team focused on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CNM-Au8: Investigational drug consisting of gold nanocrystals aimed at improving neuronal survival and function in neurodegenerative diseases. Currently undergoing clinical trials. Market share data is not yet applicable as the product is not commercially available. Competitors include Biogen, Novartis, and Roche in the broader MS market; Amylyx Pharmaceuticals, and Mitsubishi Tanabe Pharma for ALS; and Teva Pharmaceutical Industries, AbbVie for Parkinson's disease.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs and significant market opportunities. There is a high cost in this field.
Positioning
Clene Inc. positions itself as an innovator in the field of neurodegenerative disease therapeutics, utilizing nanocatalysis. Their competitive advantage lies in their unique approach to treating diseases at the cellular energy level.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is substantial, estimated to be billions of dollars annually. Clene Inc. is targeting a share of this market with its unique nanocatalysis approach, which focuses on improving neuronal energy metabolism. TAM is difficult to directly quantify due to the developmental stage of their primary assets.
Upturn SWOT Analysis
Strengths
- Proprietary nanocatalysis technology platform
- Potential for disease-modifying therapies
- Experienced leadership team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with clinical trial outcomes
- Dependence on regulatory approvals
Opportunities
- Growing prevalence of neurodegenerative diseases
- Increasing demand for effective treatments
- Potential for strategic partnerships and collaborations
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- RHHBY
- LLY
Competitive Landscape
Clene Inc. faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its novel nanocatalysis technology and potential for disease-modifying therapies, but its success depends on clinical trial results.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical trial advancements and funding rounds.
Future Projections: Future growth depends on the successful development and commercialization of CNM-Au8 and other pipeline products. Analyst estimates are speculative and highly sensitive to clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for CNM-Au8 in MS and ALS, seeking strategic partnerships, and securing additional funding.
Summary
Clene Inc. is a development-stage biopharmaceutical company with a focus on innovative therapeutics for neurodegenerative diseases. Its strength lies in its proprietary nanocatalysis technology platform, but it faces significant challenges related to clinical trial success, regulatory approvals, and competition. Successful development and commercialization of its pipeline products are critical for its future growth. The company's lack of revenue indicates it is in the research and development phase, and clinical data will be crucial for its growth and potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.